| Budget Amount *help |
¥19,760,000 (Direct Cost: ¥15,200,000、Indirect Cost: ¥4,560,000)
Fiscal Year 2012: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
|
|---|
| Research Abstract |
Recently immunotherapy is a promising cancer therapy. And Dendritic cells (DC)-based vaccination is widely tested as a promising therapeutic cancer vaccine in multiple clinical trials. But there is no utility cancer antigen for oral cancer. We have identified Mucin 1 as a critical cancer antigen in oral cancer. Furthermore we conducted the in vitro experiments to examine whether or not chemotherapeutic drugs which are used for patients with oral cancer, may enhance T cell-stimulating ability of DCsvia regulation of the expression of PD-Ls. And then we identified IL-6, IL-8 and GCSFas a prognosis biomarker of oral cancer patients. The findings obtained from this study lead to development of personalized immunochemotherapy for oral cancer patients.
|
